Trafalgar International (GCAN) Cost of Revenue (2017 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Cost of Revenue of $3376.0 for Q1 2026, down 70.17% year-over-year from $11319.0 in Q1 2025, and down 85.82% quarter-over-quarter from $23806.0 in Q4 2025.
Trafalgar International (GCAN) Cost of Revenue (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Cost of Revenue history runs 10 years deep, the most recent figure standing at $3376.0 for Q1 2026.
- In Q1 2026, Cost of Revenue fell 70.17% year-over-year to $3376.0; the TTM figure through Mar 2026 stood at $52845.0 (up 51.44% YoY), while the FY2025 annual figure was $60788.0, up 94.36% from the prior year.
- Cost of Revenue for Q1 2026 stood at $3376.0, down from $23806.0 in the prior quarter.
- The five-year high for Cost of Revenue was $23806.0 in Q4 2025, with the low at $3376.0 in Q1 2026.
- The 5-year median for Cost of Revenue is $11017.0 (2022), against an average of $11637.6.
- The sharpest annual moves came in 2022 and 2025: Cost of Revenue plunged 87.6% in 2022, then soared 273.43% in 2025.
- Greater Cannabis Company's Cost of Revenue stood at $11017.0 in 2022, then grew by 15.98% to $12777.0 in 2023, then tumbled by 50.11% to $6375.0 in 2024, then jumped by 273.43% to $23806.0 in 2025, then plunged by 85.82% to $3376.0 in 2026.
- Business Quant data shows GCAN's Cost of Revenue at $3376.0 in Q1 2026, $23806.0 in Q4 2025, and $7412.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | 3,376.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,376.00 |
| Mar 31, 2026 | 3,376.00 |
| Dec 31, 2025 | 23,806.00 |
| Dec 31, 2025 | 23,806.00 |
| Sep 30, 2025 | 7,412.00 |
| Sep 30, 2025 | 7,412.00 |
| Jun 30, 2025 | 18,251.00 |
| Jun 30, 2025 | 18,251.00 |
| Mar 31, 2025 | 11,319.00 |
| Mar 31, 2025 | 11,319.00 |
| Dec 31, 2024 | 6,375.00 |
| Dec 31, 2024 | 6,375.00 |
| Sep 30, 2024 | 9,193.00 |
| Sep 30, 2024 | 9,193.00 |
| Jun 30, 2024 | 8,007.00 |
| Jun 30, 2024 | 8,007.00 |
| Mar 31, 2024 | 7,701.00 |
| Mar 31, 2024 | 7,701.00 |
| Dec 31, 2023 | 12,777.00 |
| Dec 31, 2023 | 12,777.00 |